Bile Duct Cancer
Also known as: Cholangiocarcinoma
Methodology & AI Transparency ⓘ
Bile Duct Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Your liver makes a digestive juice called bile.
- 2 Real-world patient consensus: Synonyms for Bile Duct Cancer (C34.9): Cholangiocarcinoma (Cancer & Oncology).
- 3 Typical cash cost range: Differential triage of Bile Duct Cancer (C34.9) utilizes targeted/immunotherapy [Bile Duct Cancer C34.9].
- 4 Top reported side effects / signs: Objective lab/clinical target for Bile Duct Cancer: Complete Blood Count in Bile Duct Cancer (C34.9: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (C34.9)) and Comprehensive Metabolic & in Bile Duct Cancer (C34.9: Organ Function Panel).
Ask our AI Specialists anything about Bile Duct Cancer
What Is Bile Duct Cancer?
Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts . They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Bile duct cancer is rare. It can happen in the parts of the bile ducts that are outside or inside the liver. Cancer of the bile duct outside of the liver is much more common. Risk factors include having inflammation of the bile duct, ulcerative colitis , and some liver diseases.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Bile Duct Cancer (ICD-10 C34.9) is driven by somatic oncogenic driver in Bile Duct Cancer (C34.9: mutations); Cross-referenced with NIH MeSH (Bile Duct Neoplasms), specialists in Cancer, Oncology & Supportive Care monitor Comprehensive Metabolic & in Bile Duct Cancer (C34.9: Organ Function Panel) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Bile Duct Cancer (C34.9): abnormality detected early in Bile Duct Cancer (C34.9: on age-appropriate screening)
- • Secondary Bile Duct Cancer clinical sign: persistent painless lump, in Bile Duct Cancer (C34.9: non-healing ulcer/mole change,)
- • Symptom flares in Bile Duct Cancer correlating with Complete Blood Count in Bile Duct Cancer (C34.9: (ANC, Hemoglobin, Platelets)) deviation outside Safe hematologic reserve (C34.9)
- • Functional cancer & oncology impact requiring targeted/immunotherapy [Bile Duct Cancer C34.9] evaluation (C34.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Bile Duct Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C34.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Bile Duct Cancer (C34.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C34.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Bile Duct Cancer (C34.9: Organ Function Panel) | Preserved renal/hepatic clearance (C34.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Bile Duct Cancer (C34.9: Genomic Staging) | Guideline-concordant surveillance (C34.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bile Duct Cancer
Treatment selection for Bile Duct Cancer depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bile Duct Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Bimekizumab treatment led to rapid improvements in levels of pain and morning stiffness. The Journal of rheumatology • 2025-01-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39406403 ↗ |
| Can This Approach Help? Inside the Latest Research on Bimekizumab efficacy in male and female patients with axial spondyloarthritis: Although male patients had earlier clinical responses to bimekizumab treatment, female patients demonstrated longer-term improvements in composite and patient-reported outcomes. Rheumatology (Oxford, England) • 2026-10-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42605056 ↗ |
| Can This Approach Help? Inside the Latest Research on Evaluating the Efficacy of MamaLift Plus Digital Therapeutic Mobile App for Participants who received MamaLift Plus exhibited significant and clinically meaningful improvement in depressive symptoms compared with control. Journal of medical Internet research • 2025-07-01 • Phase III Randomized Trial | N = 95 | 88/100 | PMID 40549508 ↗ |
| New Insights on Association of mobile application information on multidisciplinary therapy and: What a 508-Participant Study Found The RJBC-APP did not improve 12-month add-on treatment compliance rate for early-stage breast cancer patients receiving MDT. Breast (Edinburgh, Scotland) • 2026-08-15 • Phase III Randomized Trial | N = 508 | 87/100 | PMID 42150214 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase III randomized controlled trial comparing local field with additional We plan to enroll 280 patients from 54 institutions over 4 years. Japanese journal of clinical oncology • 2024-01-07 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37801434 ↗ |
Bile Duct Cancer Patient Community & “People Like Me” Threads
Filter Bile Duct Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.